Lithuanian pharmaceutical manufacturer JSC Olpha is actively expanding its contract development and manufacturing organization (CDMO) services to international markets. The company, a leading player in the Baltic region, is investing in research and innovation to offer a wider range of drug development solutions. This expansion focuses on providing services throughout the entire drug lifecycle, from initial development to commercial manufacturing. Olpha aims to capitalize on growing global demand for outsourced pharmaceutical services, particularly in Western Europe and North America. The company highlights its high-quality standards and competitive pricing as key advantages. This strategic move is expected to boost Olpha’s revenue and solidify its position as a significant player in the pharmaceutical industry. Further details regarding specific investment amounts and target markets are anticipated in the coming months.